The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 Japanese subgroup analysis.
 
Norihiko Tsuchiya
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Merck; MSD; Novartis; Pfizer; Sanofi; Takeda
Research Funding - Pfizer (Inst); Takeda (Inst)
 
Yoshiaki Yamamoto
No Relationships to Disclose
 
Hirotsugu Uemura
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Kissei Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Takeda (Inst)
 
Hiro-Omi Kanayama
Research Funding - Astellas Pharma (Inst); Fujifilm (Inst); Kissei Pharmaceutical (Inst); MSD K.K (Inst); Nihon Medi-Physics (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Masatoshi Eto
Consulting or Advisory Role - Bristol-Myers Squibb; Chugai Pharma; Eisai; Johnson & Johnson; Merck; MSD Oncology; Novartis; Olympus; Ono Pharmaceutical; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; Janssen Oncology; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Kissei Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Takeda (Inst)
 
Hideaki Miyake
Honoraria - Pfizer
Consulting or Advisory Role - Pfizer
Research Funding - Pfizer (Inst)
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Incyte; Ipsen; Johnson & Johnson; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Incyte; Ipsen; Johnson & Johnson; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); EMD Serono (Inst); Exelixis (Inst); Ipsen (Inst); Johnson & Johnson (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche
 
Mizuki Yoshida
Employment - Pfizer
 
Yuichiro Koide
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Yoshiko Umeyama
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Alessandra Di Pietro
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Yoshihiko Tomita
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Chugai Pharma; Novartis; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst)